242 related articles for article (PubMed ID: 21269506)
1. Activation of the dopamine 1 and dopamine 5 receptors increase skeletal muscle mass and force production under non-atrophying and atrophying conditions.
Reichart DL; Hinkle RT; Lefever FR; Dolan ET; Dietrich JA; Sibley DR; Isfort RJ
BMC Musculoskelet Disord; 2011 Jan; 12():27. PubMed ID: 21269506
[TBL] [Abstract][Full Text] [Related]
2. Corticotropin releasing factor 2 receptor agonists reduce the denervation-induced loss of rat skeletal muscle mass and force and increase non-atrophying skeletal muscle mass and force.
Hinkle RT; Donnelly E; Cody DB; Bauer MB; Sheldon RJ; Isfort RJ
J Muscle Res Cell Motil; 2004; 25(7):539-47. PubMed ID: 15711884
[TBL] [Abstract][Full Text] [Related]
3. Treatment with a corticotrophin releasing factor 2 receptor agonist modulates skeletal muscle mass and force production in aged and chronically ill animals.
Hinkle RT; Lefever FR; Dolan ET; Reichart DL; Zwolshen JM; Oneill TP; Maloney KG; Mattson JP; Ferreira LF; Musch TI; Poole DC; Isfort RJ
BMC Musculoskelet Disord; 2011 Jan; 12():15. PubMed ID: 21235761
[TBL] [Abstract][Full Text] [Related]
4. Activation of the vasoactive intestinal peptide 2 receptor modulates normal and atrophying skeletal muscle mass and force.
Hinkle RT; Donnelly E; Cody DB; Sheldon RJ; Isfort RJ
J Appl Physiol (1985); 2005 Feb; 98(2):655-62. PubMed ID: 15649881
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D1/D5 receptor activation reverses NMDA receptor-dependent long-term depression in rat hippocampus.
Mockett BG; Guévremont D; Williams JM; Abraham WC
J Neurosci; 2007 Mar; 27(11):2918-26. PubMed ID: 17360914
[TBL] [Abstract][Full Text] [Related]
6. Grip force, EDL contractile properties, and voluntary wheel running after postdevelopmental myostatin depletion in mice.
Personius KE; Jayaram A; Krull D; Brown R; Xu T; Han B; Burgess K; Storey C; Shah B; Tawil R; Welle S
J Appl Physiol (1985); 2010 Sep; 109(3):886-94. PubMed ID: 20595537
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tetrodotoxin-resistant sodium current in dorsal root ganglia neurons mediated by D1/D5 dopamine receptors.
Galbavy W; Safaie E; Rebecchi MJ; Puopolo M
Mol Pain; 2013 Nov; 9():60. PubMed ID: 24283218
[TBL] [Abstract][Full Text] [Related]
8. Flavan 3-ol delays the progression of disuse atrophy induced by hindlimb suspension in mice.
Ito M; Kudo N; Miyake Y; Imai T; Unno T; Yamashita Y; Hirota Y; Ashida H; Osakabe N
Exp Gerontol; 2017 Nov; 98():120-123. PubMed ID: 28807824
[TBL] [Abstract][Full Text] [Related]
9. Involvement of cAMP/EPAC/Akt signaling in the antiproteolytic effects of pentoxifylline on skeletal muscles of diabetic rats.
Arcaro CA; Assis RP; Zanon NM; Paula-Gomes S; Navegantes LCC; Kettelhut IC; Brunetti IL; Baviera AM
J Appl Physiol (1985); 2018 Mar; 124(3):704-716. PubMed ID: 29357512
[TBL] [Abstract][Full Text] [Related]
10. Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation.
Beehler BC; Sleph PG; Benmassaoud L; Grover GJ
Exp Biol Med (Maywood); 2006 Mar; 231(3):335-41. PubMed ID: 16514182
[TBL] [Abstract][Full Text] [Related]
11. Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.
Conroy JL; Free RB; Sibley DR
ACS Chem Neurosci; 2015 Apr; 6(4):681-92. PubMed ID: 25660762
[TBL] [Abstract][Full Text] [Related]
12. Acute antibody-directed myostatin inhibition attenuates disuse muscle atrophy and weakness in mice.
Murphy KT; Cobani V; Ryall JG; Ibebunjo C; Lynch GS
J Appl Physiol (1985); 2011 Apr; 110(4):1065-72. PubMed ID: 21270350
[TBL] [Abstract][Full Text] [Related]
13. Urocortin II treatment reduces skeletal muscle mass and function loss during atrophy and increases nonatrophying skeletal muscle mass and function.
Hinkle RT; Donnelly E; Cody DB; Bauer MB; Isfort RJ
Endocrinology; 2003 Nov; 144(11):4939-46. PubMed ID: 12960070
[TBL] [Abstract][Full Text] [Related]
14. Balanced Diet-Fed Fat-1 Transgenic Mice Exhibit Lower Hindlimb Suspension-Induced Soleus Muscle Atrophy.
Marzuca-Nassr GN; Murata GM; Martins AR; Vitzel KF; Crisma AR; Torres RP; Mancini-Filho J; Kang JX; Curi R
Nutrients; 2017 Oct; 9(10):. PubMed ID: 28984836
[TBL] [Abstract][Full Text] [Related]
15. The effect of creatine supplementation on mass and performance of rat skeletal muscle.
Young RE; Young JC
Life Sci; 2007 Aug; 81(9):710-6. PubMed ID: 17707068
[TBL] [Abstract][Full Text] [Related]
16. Myostatin dysfunction does not protect from fasting-induced loss of muscle mass in mice.
Fokin A; Minderis P; Venckunas T; Lionikas A; Kvedaras M; Ratkevicius A
J Musculoskelet Neuronal Interact; 2019 Sep; 19(3):342-353. PubMed ID: 31475942
[TBL] [Abstract][Full Text] [Related]
17. Expression of MuRF1 or MuRF2 is essential for the induction of skeletal muscle atrophy and dysfunction in a murine pulmonary hypertension model.
Nguyen T; Bowen TS; Augstein A; Schauer A; Gasch A; Linke A; Labeit S; Adams V
Skelet Muscle; 2020 Apr; 10(1):12. PubMed ID: 32340625
[TBL] [Abstract][Full Text] [Related]
18. Effects of pleiotrophin overexpression on mouse skeletal muscles in normal loading and in actual and simulated microgravity.
Camerino GM; Pierno S; Liantonio A; De Bellis M; Cannone M; Sblendorio V; Conte E; Mele A; Tricarico D; Tavella S; Ruggiu A; Cancedda R; Ohira Y; Danieli-Betto D; Ciciliot S; Germinario E; Sandonà D; Betto R; Camerino DC; Desaphy JF
PLoS One; 2013; 8(8):e72028. PubMed ID: 24015201
[TBL] [Abstract][Full Text] [Related]
19. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.
Murphy KT; Chee A; Gleeson BG; Naim T; Swiderski K; Koopman R; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2011 Sep; 301(3):R716-26. PubMed ID: 21677277
[TBL] [Abstract][Full Text] [Related]
20. Oral fucoidan improves muscle size and strength in mice.
McBean SE; Church JE; Thompson BK; Taylor CJ; Fitton JH; Stringer DN; Karpiniec SS; Park AY; van der Poel C
Physiol Rep; 2021 Feb; 9(3):e14730. PubMed ID: 33527754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
